Torrent Pharmaceuticals has appointed Geena Malhotra as its new Chief Technology Officer, effective February 1, 2026. Malhotra brings nearly four decades of global experience in R&D, manufacturing, supply chain, and sustainability. Her expertise will drive innovation and technological advancement within the company. The appointment reflects Torrent Pharma’s commitment to strengthening its leadership team.
Leadership Change at Torrent Pharma
Torrent Pharmaceuticals has announced the appointment of Geena Malhotra as Chief Technology Officer (CTO), effective February 1, 2026. This move is aimed at bolstering the company’s technological capabilities and driving future innovation.
About Geena Malhotra
Geena Malhotra is a seasoned pharmaceutical leader with extensive global experience in R&D, manufacturing, supply chain, and sustainability. Prior to this appointment, she served as Managing Director of Signet Excipients, driving strategic growth and digital transformation across the pharma and biopharma sectors. Her previous role included Global CTO and President at Cipla Ltd.
Malhotra’s Expertise
Malhotra’s experience includes overseeing operations in R&D and manufacturing, fostering high-performance organizational cultures with a focus on ESG. She has played a key role in obtaining around 50 international patents in formulations, inhalation devices, and drug delivery systems, supporting commercial products in more than 80 countries. She has also received multiple awards for scientific excellence, innovation, and leadership impact.
Awards and Recognition
Malhotra has received the Eminent Scientist Award for global impact on ARV affordability, respiratory innovation, and sustainability. Additional awards include the FDD Leadership Award (2017) for achievement in formulation development and drug delivery, the Thomson Reuters Innovation Award (2012), and the Eminent Researcher Award (2007).
Source: BSE
